Objective:To explore the clinical characteristics and influencing factors of hematologic disease patients with chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their effects on the prognosis of patients.Methods:The clinical data of 225 hematologic disease patients who underwent allo-HSCT from January 2014 to February 2021 in the First Affiliated Hospital of Chongqing Medical University were retrospectively analyzed. The efficacy of allo-HSCT, post-transplantation infection, as well as the incidence of cGVHD and its related factors, and its effect on the overall survival (OS) rate, disease-free survival (DFS) rate, cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) rate of patients according to Seattle diagnostic criteria and National Institutes of Health (NIH) diagnostic criteria were analyzed.Results:All 225 hematologic disease patients had hematopoietic reconstruction after allo-HSCT. Among the 225 patients, 156 patients (69.33%) had early infection (207 times), and 92 patients (40.89%) had late infection (107 times). According to the Seattle diagnostic criteria, 58 patients developed cGVHD (111 times), with a cumulative incidence of 39.5%. The involved organs included skin (33 times), liver (32 times), eyes (19 times), lung (11 times), oral cavity (10 times), intestine (4 times) and hematological system (twice). Multivariate Cox regression analysis showed that acute graft-versus-host disease (aGVHD) was an independent influencing factor for cGVHD ( HR= 3.706, 95% CI 2.025-6.783, P<0.001). Compared to patients without cGVHD, patients with cGVHD had lower 5-year CIR (4.0% vs. 21.8%, P= 0.010) and higher 5-year NRM rate (25.5% vs. 11.8%, P= 0.029), while 5-year OS rate (72.5% vs. 73.6%, P= 0.908) and DFS rate (64.6% vs. 65.9%, P= 0.670) between the two groups had no statistical difference. Compared to patients with limited cGVHD, patients with extensive cGVHD had lower 5-year OS rate (56.0% vs. 83.9%, P= 0.035), lower 5-year DFS rate (52.0% vs. 73.4%, P = 0.038) and higher 5-year NRM rate (43.0% vs. 13.0%, P = 0.018). More erythrocyte suspension infusion during the transplantation was an independent influencing factor for early infection ( P = 0.011). Blood type incompatibility between donor and recipient ( P = 0.017), limited cGVHD ( P = 0.039) and extensive cGVHD ( P = 0.003) were independent influencing factors for late infection. According to the NIH diagnostic criteria, 5 patients (8.62%) who developed cGVHD after 100 days of transplantation were reclassified as aGVHD, and 12 patients (20.69%) were reclassified as overlap syndrome. The cumulative incidence of cGVHD was 36.4%, and aGVHD was the only independent influencing factor for cGVHD ( P<0.001). Compared to patients without cGVHD, patients with cGVHD had lower 5-year CIR (6.7% vs.21.7%, P = 0.006) and higher 5-year NRM rate (26.1% vs. 12.0%, P = 0.035), while 5-year OS rate (73.7% vs. 73.2%, P = 0.845) and DFS rate (64.9% vs. 65.7%, P = 0.522) between the two groups had no statistical difference. Conclusions:The incidence of cGVHD after allo-HSCT in hematologic disease patients is high, and there are many organs involved. cGVHD can reduce the relapse rate of patients, but severe cGVHD increases the mortality of patients. aGVHD is the only independent influencing factor for cGVHD.